Entyvio (vedolizumab) / Takeda - LARVOL DELTA

Novel Agents on the Therapeutic Horizon For Paediatric Inflammatory Bowel Diseases: An Analysis of Clinical Trials Registries. (PubMed, Paediatr Drugs) - "Efforts to expedite approval of new agents in pIBD are warranted to ensure timely access to effective medications. Consideration for novel trial designs alongside continued engagement with regulatory bodies, sponsors, and the academic pIBD community is essential to advance drug approvals for pIBD."

Journal • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Pediatrics

A DUAL-MODALITY STRATEGY USING ROUTINE BIOPSY AND CLINICAL PROFILE PREDICTS LONG-TERM VEDOLIZUMAB EFFICACY (UEGW 2026) - "Full abstract will be published on the day of presentation"

Biopsy • Clinical • Late-breaking abstract

COMPARATIVE EFFECTIVENESS OF FIRST-LINE BIOLOGIC THERAPIES IN BIOLOGIC-NAÏVE ADULTS WITH ULCERATIVE COLITIS: A MULTICENTRE REAL-WORLD STUDY (UEGW 2026) - "This multicentre retrospective cohort included patients initiating infliximab, adalimumab, vedolizumab, ustekinumab or mirikizumab as first-line biologic therapy. In this multicentre real-world cohort, mirikizumab achieved the highest 6-month SFCR probability and showed nominal superiority over all comparators after weighting. Infliximab also outperformed adalimumab and vedolizumab. However, FCP declined significantly and comparably across treatments, suggesting that differences in clinical remission were not paralleled by differential biochemical response trajectories."

Clinical • HEOR • Real-world • Real-world evidence • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

IMPACT OF THE ORDER OF THE FIRST TWO BIOLOGIC THERAPIES IN INFLAMMATORY BOWEL DISEASE: THE SECUTEM STUDY FROM THE ENEIDA REGISTRY (UEGW 2026) - "The order of the first two biologic therapies in patients with IBD significantly impacts the durability of the overall treatment sequence. Initial use of an anti-TNF agent, particularly infliximab, is associated with greater treatment durability compared with starting with vedolizumab, ustekinumab, or adalimumab."

Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis

DRUG SAFETY IN LATE-ONSET IBD: A NATIONWIDE COHORT STUDY (UEGW 2026) - "The primary outcome was occurrence of a treatment-related adverse event (AE) to 5-ASA, thiopurines, anti-TNF (infliximab, adalimumab and golimumab [UC only]), vedolizumab and ustekinumab. In one of the largest nationwide cohort studies to date, we have found no increased risk of overall AEs in LO-IBD patients treated with 5-ASA and biologics. Thiopurines were associated with increased AEs in LO-IBD, highlighting the caution required when treating this group. These findings support the use of biologics in late-onset IBD."

Clinical • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Inflammatory Bowel Disease • Ulcerative Colitis

INCREMENTAL PROGNOSTIC VALUE OF ENDOSCOPIC AND HISTOLOGIC REMISSION ADDED TO CLINICAL REMISSION IN ULCERATIVE COLITIS: A MULTICENTRE REAL-WORLD LANDMARK ANALYSIS (UEGW 2026) - "Aims & We conducted a multicentre retrospective cohort study across 9 Italian IBD centres, including adult UC patients receiving advanced therapies (anti-TNF, vedolizumab, ustekinumab, JAK inhibitors, S1P modulators). In this large real-world multicentre cohort, achievement of deeper remission at the early maintenance landmark was associated with progressively lower risk of long-term disease progression, with the strongest protection conferred by clearance-level stringency (pMayo=0, Geboes≤1) rather than by the mere addition of histologic remission. These findings support disease clearance as defined by IOIBD, not simply the presence of histology in remission, as the clinically meaningful treat-to-target endpoint in UC."

Clinical • Real-world • Real-world evidence • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

SWITCHING FROM USTEKINUMAB ORIGINATOR TO BIOSIMILAR: NO ADVERSE IMPACT ON INFLAMMATORY BOWEL DISEASE CONTROL AND WELL TOLERATED AT 12 MONTHS IN A UK MULTICENTRE STUDY (UEGW 2026) - "Prior treatment exposure was anti-tumour necrosis factor agents (anti-TNF) in 543 (80%) patients, vedolizumab in 32 (5%) patients and both anti-TNF and vedolizumab in 94 (14%) patients... We observed high treatment persistence rates and stable clinical disease activity and biomarkers with ustekinumab biosimilars one year after switch. Biosimilar ustekinumab was well tolerated and appears to be safe."

Clinical • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis • CRP

REAL-WORLD TRANSMURAL HEALING RATES ASSESSED BY INTESTINAL ULTRASOUND DURING THE FIRST YEAR OF BIOLOGIC THERAPY IN CROHN'S DISEASE (UEGW 2026) - " A total of 190 patients (median age: 33 [27-49], male: 49%, L1-62%, L2-4%, L3-34%) starting on biologics were included (anti-TNF [n=67], vedolizumab (VDZ) [n=77], and ustekinumab (UST) [n=46]). In this real-world cohort, sonographic response to biologic therapy occurred early and progressed over time, largely independent of biologic class, supporting IUS as a robust tool for monitoring therapeutic response in CD."

Clinical • Real-world • Real-world evidence • Crohn's disease • Gastroenterology • Immunology • Inflammatory Bowel Disease

ACHIEVING CROHN'S DISEASE TREATMENT TARGETS IN CLINICAL PRACTICE ACCORDING TO THE STRIDE-II RECOMMENDATIONS (UEGW 2026) - "Among these, 44.9% initiated anti-TNF therapy, 25.7% Ustekinumab, 16.0% Vedolizumab, and 13.4% other advanced therapies, including JAK inhibitors and IL-23 antagonists. In this real-world cohort of patients with CD starting a new advanced therapy, evaluation and achievement of STRIDE-II treatment targets was generally low in the proposed timeframes. This suggests that these recommendations may be challenging to assess routinely and attain in clinical practice. Although STRIDE-II provides an important therapeutic framework, further refinement of future recommendations is warranted to align with daily practice."

Clinical • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • CRP • IL23A

COMPARATIVE STUDY ON THE EFFECTIVENESS, DURABILITY, AND SAFETY OF UPADACITINIB VERSUS RISANKIZUMAB AFTER ANTI-TNF FAILURE IN CROHN'S DISEASE: THE U-PARIS STUDY OF ENEIDA (UEGW 2026) - "Aims & Aims: to compare the durability and effectiveness of UPA and RSK after biologic failure in CD; to identify risk factors for relapse and for therapy discontinuation; and to explore safety profile of UPA and RSK in this scenario. adult patients from the prospectively-maintained ENEIDA registry of GETECCU who received UPA or RSK as second- (after 1 anti-TNF) or third-line (after 2 anti-TNFs, 1 anti-TNF+vedolizumab, or 1 anti-TNF+ustekinumab) with ≥12 weeks of follow-up, were included. UPA and RSK are effective options after biologic failure in CD patients. Both agents showed relatively high treatment durability with greater persistence observed for RSK in third-line. CD behaviour and UPA treatment (vs."

Clinical • Acne Vulgaris • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammatory Bowel Disease • Solid Tumor

EVALUATING THE VEDOLIZUMAB CLINICAL DECISION SUPPORT TOOL ACROSS ADVANCED THERAPIES IN CROHN'S DISEASE (UEGW 2026) - "Initial treatments included anti-TNF therapy (n=135; 25%), vedolizumab (n=127; 24%), ustekinumab (n=110; 21%), anti-IL23 (n=123; 23%) and JAK inhibitors (n=40; 7.5%). In this large real-world study, we found that the CDST was significantly associated with the probability of reaching most relevant clinical outcomes, with similar performances across advanced therapies."

Clinical • Metastases • Crohn's disease • Gastroenterology • Immunology • Inflammatory Bowel Disease

REAL-WORLD, LONG-TERM EFFECTS OF BIOLOGICAL THERAPIES AND SMALL MOLECULES IN ULCERATIVE COLITIS – A SYSTEMATIC REVIEW AND META ANALYSIS (UEGW 2026) - "The only consistently reported predictor of colectomy was elevated C-reactive protein at IFX-initiation.2,31 In total, eight malignancies and five deaths were reported with infliximab, adalimumab, golimumab, tofacitinib, ustekinumab and vedolizumab during a 4-year follow-up period. In real-world, approximately one-third to one-half of patients remain on biologic or small molecule therapy beyond four years. Prior biologic treatment was associated with reduced treatment persistence and increased colectomy risk. These data highlight the long-term impact of advanced therapies, supporting evidence-based expectation settings for both clinicians and patients."

Real-world • Real-world evidence • Retrospective data • Review • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis • CRP

LONGITUDINAL IMPACT OF DISABILITY ON LONG-TERM CLINICAL OUTCOMES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A PROSPECTIVE MULTICENTER STUDY (UEGW 2026) - "Distinct therapeutic patterns emerged across disability trajectories: patients with moderate-to-severe disability were more often on advanced therapies at baseline (72.7%); persistently mild disability was mainly associated with conventional therapy (27.7%) and anti-TNF agents (45%), whereas persistently severe disability showed lower anti-TNF use (31.2%) and greater exposure to vedolizumab (15%), anti-IL-23 ± 12(18.7%) and JAKi (11.2%), consistent with a more refractory course... Moderate-to-severe disability independently predicted clinical relapse and hospitalisation at 24 months. These findings support incorporating disability assessment in clinical practice to monitor patients with IBD and stratify progression risk"

Clinical • Clinical data • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • IL23A

REAL-WORLD STUDY OF VEDOLIZUMAB-TREATED PAEDIATRIC PATIENTS WITH INFLAMMATORY BOWEL DISEASE USING DATA FROM THE IMPROVECARENOW REGISTRY (UEGW 2026) - "This analysis of real-world data on off-label use of IV VDZ in paediatric patients with IBD demonstrated that a large proportion of patients achieved clinical remission and response at Week 14 and Week 54. Most patients received VDZ with 300 mg dosing. Patients discontinued VDZ treatment after a median of ~1.5 years in CD and ~2.5 years in UC."

Clinical • Real-world • Real-world evidence • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Pediatrics • Ulcerative Colitis

REAL‑WORLD COMPARATIVE OUTCOMES OF VEDOLIZUMAB AND USTEKINUMAB IN BIOLOGIC‑NAÏVE AND BIOLOGIC‑EXPERIENCED PATIENTS WITH CROHN'S DISEASE IN THE UNITED STATES AND CANADA (UEGW 2026) - "VDZ and UST exhibited comparable effectiveness in patients with CD. Rates of mucosal healing were higher in VDZ- than UST-treated bio-naïve patients, consistent with prior findings.1 Safety trends were generally similar between VDZ and UST cohorts, particularly for anti-TNF-experienced patients. These results support positioning VDZ as first- or later-line advanced therapy in patients with CD."

Clinical • Real-world • Real-world evidence • CNS Disorders • Crohn's disease • Gastroenterology • Immunology • Inflammatory Bowel Disease • CRP

MULTI-OMICS BIOMARKERS FOR PREDICTING TREATMENT RESPONSE IN INFLAMMATORY BOWEL DISEASE (UEGW 2026) - "Aims & A multi-omics analysis was performed integrating transcriptomics, proteomics, metabolomics, and metagenomics across intestinal tissue, serum, urine, serum-derived extracellular vesicles (EVs), and stool from 130 IBD patients treated with anti-TNFα, ustekinumab, vedolizumab, or tofacitinib. These findings establish a comprehensive framework for precision therapy in IBD, identifying predictive biomarkers with translational potential to optimize personalized therapy, minimize ineffective treatment, and reduce disease burden."

Biomarker • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Metabolic Disorders • Ulcerative Colitis

PRECISION MECHANISMS OF RESPONSE TO BIOLOGICS AND TOFACITINIB IN INFLAMMATORY BOWEL DISEASE (UEGW 2026) - "Aims & We performed an integrated multi-omic longitudinal analysis in 103 patients with moderate-to-severe IBD (53 CD, 50 UC) initiating anti-TNF, ustekinumab, vedolizumab, or tofacitinib. IBD therapeutic response reflects a drug-specific but system-wide biological reorganisation spanning host immunity, tissue biology, and the gut microbiome. Rather than discrete pathway activation, biologics and small molecules induce coordinated multi-omic rewiring of disease networks. These findings provide a mechanistic framework for precision stratification of IBD therapies."

Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis • LCP1

STUDY OF TOFACITINIB FOR THE TREATMENT OF CHRONIC POUCHITIS (STOPIT): AN OPEN LABEL INDUCTION WITH RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED MAINTENANCE VS WITHDRAWAL (UEGW 2026) - "Introduction: Chronic pouchitis affects up to 20% of patients following ileal pouch–anal anastomosis for ulcerative colitis and remains difficult to treat.(1) To date, vedolizumab is the only treatment that has demonstrated efficacy for chronic pouchitis in a double-blind randomised controlled trial (DBRCT).(2) We evaluated the efficacy of tofacitinib in a DBRCT and explored predictors of response. Tofacitinib was associated with high rates of clinical and endoscopic remission during induction in chronic pouchitis and was superior to placebo in maintenance of clinical response. Baseline IL-18 and dynamic cytokine suppression may serve as biomarkers of treatment response, supporting immune stratification in this population."

Clinical • Gastrointestinal Disorder • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis • CXCL8 • IL18

MOLECULAR CHARACTERISATION OF RESPONDERS TO VEDOLIZUMAB IDENTIFIED BY SYMPTOM RESPONSE TRAJECTORIES, STUDY ENDPOINTS, AND MUCOSAL GENE TRANSCRIPTOMIC ANALYSES (UEGW 2026) - "Analysis of differential gene expression (DGE) and pathways was conducted at baseline, week 14 and week 52, to distinguish between response groups in patients treated with adalimumab (ADA) and vedolizumab (VDZ). This analysis extends on prior work showing that endpoint response and symptom response trajectories define biologically different UC patient subpopulations with different prospects to achieve CDC at week 52. These findings add clarity to the transcriptomics analysis by identifying discreet and shared pathways linked to NR to VDZ or ADA."

Gastroenterology • Gastrointestinal Disorder • Inflammatory Bowel Disease • Ulcerative Colitis

AI-POWERED QUANTIFICATION OF INFLAMMATORY MICROENVIRONMENT HISTOLOGY AND TRANSCRIPTOMICS REVEALS HISTOLOGICAL CORRELATES OF ULCERATIVE COLITIS DISEASE ACTIVITY WITH BIOLOGIC THERAPY IN THE VARSITY TRIAL (UEGW 2026) - P3 | "Introduction: Biologic therapy with vedolizumab (VDZ) or adalimumab (ADA) can lead to histological and endoscopic improvement in patients with ulcerative colitis (UC), but their effects on the cellular and molecular inflammatory microenvironment (IME) remain understudied. Using an ML-based approach to assess the UC IME, features related to neutrophils, granulation tissue and goblet cells that correlated with RHI severity were identified. VDZ- or ADA-specific differences were further identified at Week 52. Despite a similar RHI distribution at Week 52, the underlying histology between treatment groups was different, reflecting potential differences in mechanism of action–driven changes in the IME."

Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

QUANTITATIVE HISTOLOGIC FEATURES OF THE INFLAMMATORY MICROENVIRONMENT BEFORE AND AFTER VEDOLIZUMAB INDUCTION THERAPY ARE ASSOCIATED WITH ENDOSCOPIC RESPONSE IN PATIENTS WITH ULCERATIVE COLITIS (UEGW 2026) - P3 | "Using an ML-based approach to assess the IME in patients with UC, a significant association between goblet cell density and the severity of MES was identified. Certain features at baseline and Week 14 were found to predict endoscopic response to VDZ therapy, with immune cell abundance and goblet cell density exhibiting the highest predictive power. These findings highlight the potential of histological biomarkers to predict therapeutic outcomes in VDZ-treated patients with UC and support further validation of these results in larger cohorts.*IBDExplore is for research use only."

Clinical • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

A SWEDISH REGISTER-BASED STUDY EVALUATING THE PERFORMANCE OF A CLINICAL DECISION SUPPORT TOOL (CDST) FOR VEDOLIZUMAB IN CROHN'S DISEASE (UEGW 2026) - "In this real-world cohort, VDZ-CDST did not predict clinical remission at week 52. However, it showed modest performance for other vedolizumab-related outcomes: biochemical remission, treatment persistence, and surgery-free survival. Although individual-level discrimination was limited in this setting, the score provides a framework for further refinement toward individualized risk assessment."

Clinical • Crohn's disease • Gastroenterology • Immunology • Inflammatory Bowel Disease

NATURAL HISTORY AND RISK FACTORS OF IMMUNE ENTEROCOLITIS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES TREATED WITH IMMUNE CHECKPOINT INHIBITORS (UEGW 2026) - "The majority of patients (84%) had a quiescent disease at ICI initiation and 50 were receiving treatment for IBD concomitant to the start of ICI (5-ASA, systemic immunosuppression and vedolizumab in 35, 12 and 4 patients)... In this cohort, 33% of IBD patients treated with ICIs presented an imDC and subsequently 18% had to withdraw therapy. In univariate analysis, the type of ICI and IBD disease location was significantly associated with imDC."

Checkpoint inhibition • Clinical • Gastroenterology • Gastrointestinal Cancer • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Oncology • Solid Tumor

SAFETY AND EFFECTIVENESS OF ADVANCED THERAPIES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND COMPENSATED CIRRHOSIS. HEP-IBD STUDY. A STUDY FROM THE YOUNG GROUP OF GETECCU (UEGW 2026) - "Consecutive IBD patients with an established diagnosis of compensated cirrhosis (Child A or Child B≤8) who received at least induction with infliximab, adalimumab, golimumab, ustekinumab, vedolizumab, tofacitinib, upadacitinib, risankizumab, mirikizumab or filgotinib between January 2000 and September 2024, were eligible. These data suggest that the use of advanced therapies is feasible in patients with compensated cirrhosis, with acceptable treatment persistence rates and a low risk of hepatic decompensation, without clear differences between anti-TNF and non–anti-TNF therapies."

Clinical • Metastases • Crohn's disease • Fibrosis • Gastroenterology • Gastrointestinal Disorder • Hepatocellular Cancer • Hepatology • Immunology • Inflammation • Inflammatory Bowel Disease • Liver Cirrhosis • Liver Failure • Metabolic Dysfunction-Associated Steatotic Liver Disease • Solid Tumor • Ulcerative Colitis

BEYOND THE PDAI: MONTH-3 SES-CD AS AN INDEPENDENT ENDOSCOPIC PREDICTOR OF BIOLOGIC THERAPY INITIATION AFTER ILEAL POUCH-ANAL ANASTOMOSIS — A RETROSPECTIVE MULTICENTER COHORT (UEGW 2026) - " Of 91 patients (53.8% male; mean age 39±11 years; 90.1% ulcerative colitis), 12.1% (n=11) initiated biologic therapy, predominantly vedolizumab... Month-3 SES-CD is the most robust independent endoscopic predictor of biologic initiation after IPAA, outperforming ePDAI across all diagnostic metrics. The 100% biologic escalation rate among SES-CD>3/ePDAI≤1 discordant cases mechanistically establishes that the binary ePDAI misses deep focal ulceration captured only by quantitative grading. SES-CD should be adopted as a complementary risk-stratification tool at the month-3 pouchoscopy, without replacing PDAI/mPDAI as the diagnostic standard or trial endpoint."

Retrospective data • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Inflammatory Bowel Disease • Ulcerative Colitis